BioSpace News Archive

Venatorx Pharmaceuticals announced that it has been awarded a contract by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services to advance a novel series of Penicillin Binding Protein Inhibitors targeting multi-drug resistant Acinetobacter baumannii through Phase 1 clinical testing.

Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, August 10, 2020, it will release second quarter 2020 financial results and host a conference call at 5:00 p.m. Eastern Daylight Time / 2:00 p.m. Pacific Daylight Time to discuss the financial results and recent business developments.

vTv Therapeutics Inc . (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer’s Association International Conference (AAIC), held virtually, July 27–31, 2020. The poster presentation will highlight additional analyses of the clinical data from the STEADFAST Study of azeliragon showing the relative contribution of the effects on individual test items, as well as on the higher level cognitive and/or f

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced AMAG and Palatin Technologies, Inc. have mutually terminated the January 2017 license agreement pursuant to which AMAG was granted exclusive rights to develop and commercialize Vyleesi® (bremelanotide), a melanocortin receptor agonist indicated for th

VitalHub Corp. is pleased to announce they have been selected by the National Health Service as one of two vendors to be included within the new NHS Framework Agreement.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that a paper presenting a post-hoc data analysis of TAVALISSE ® (fostamatinib disodium hexahydrate) tablets, as well as accompanying commentary have been published in the British Journal of Haematology. TAVALISSE, Rigel’s oral spleen tyrosine kinase (SYK) inhibi

LGM Pharma today announced that it has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc.

Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that the underwriters of its global offering of new ordinary shares, comprising American Depositary Shares (“ADSs”) and ordinary shares (the “Global Offering”), have exercised, in part, their over-allotment option.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has submitted an application with the National Institute of Allergy and Infectious Disease (NIA

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Zenocutuzumab (Zeno) for the treatment of patients with pancreatic cancer. Zeno is a first in class bispecific antibody that potently binds to